Profile of immunologic recovery in HIV-infected Ugandan adults after antiretroviral therapy

AIDS Research and Human Retroviruses

Volumn 23, Issue 7, 2007, Pages 900-905

  Baker, Chris A R ^a   Emenyonu, Nneka ^b   Ssewanyana, Isaac ^c   Jones, Norman G ^a   Elrefaei, Mohamed ^a   Nghania, Frehd ^c   Nakiwala, Justine ^c   Andia, Irene ^b   Clark, Richard ^b   Martin, Jeffrey ^b   Bangsberg, David R ^b   Cao, Huyen ^a  

^a CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JOINT CLINICAL RESEARCH CENTRE   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD27 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45RA ANTIGEN; CD8 ANTIGEN; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; UGANDA; VIRUS INHIBITION; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; MALE; UGANDA;

EID: 34547962119     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0309     Document Type: Article

References (62)

1. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al.: Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002;360:119-129.
2. Autran B, Carcelaint G, Li TS, Gorochov G, Blanc C, Renaud M, et al.: Restoration of the immune system with anti-retroviral therapy. Immunol Lett 1999;66:207-211.
3. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al.: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-116.
4. Pakker NG, Roos MT, van Leeuwen R, de Jong MD, Koot M, Reiss P, et al.: Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:318-326.
5. Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, et al.: Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005;41:361-372.
6. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, and Montaner JS: Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286:2568-2577.
7. Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA, Lange JM, et al.: Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003;17: 1881-1888.
8. Benito JM, Lopez M, Lozano S, Ballesteros C, Capa L, Martinez P, et al.: CD4+ T cell recovery beyond the first year of complete suppression of viral replication during highly active antiretroviral therapy is not influenced by CD8+ T cell activation. J Infect Dis 2005;192:2142-2146.
9. Almeida CA, Price P, and French MA: Immune activation in patients infected with HIV type 1 and maintaining suppression of viral replication by highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2002;18:1351-1355.
10. Al-Harthi L, Voris J, Patterson BK, Becker S, Eron J, Smith KY, et al.: Evaluation of the impact of highly active antiretroviral therapy on immune recovery in antiretroviral naive patients. HIV Med 2004;5:55-65.
11. Mildvan D, Bosch RJ, Kim RS, Spritzler J, Haas DW, Kuritzkes D, et al.: Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. J Infect Dis 2004;189:1811-1820.
12. Benito JM, Lopez M, Lozano S, Ballesteros C, Martinez P, Gonzalez-Lahoz J, and Soriano V: Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005;38:373-381.
13. Anthony KB, Yoder C, Metcalf JA, DerSimonian R, Orenstein JM, Stevens RA, et al.: Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. J Acquir Immune Defic Syndr 2003;33:125-133.
14. Spira S, Wainberg MA, Loemba H, Turner D, and Brenner BG: Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother 2003; 51:229-240.
15. Pieniazek D, Rayfield M, Hu DJ, Nkengasong J, Wiktor SZ, Downing R, et al.: Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group. AIDS 2000;14:1489-1495.
16. Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-Kane C, et al.: Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: Evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 2000;38: 3919-3925.
17. Eggena MP, Barugahare B, Okello M, Mutyala S, Jones N, Ma Y, et al.: T cell activation in HIV-seropositive Ugandans: Differential associations with viral load, CD4+ T cell depletion, and coinfection. J Infect Dis 2005;191:694-701.
18. Bentwich Z, Kalinkovich A, and Weisman Z: Immune activation is a dominant factor in the pathogenesis of African AIDS. Immunol Today 1995;16:187-191.
19. Messele T, Abdulkadir M, Fontanet AL, Petros B, Hamann D, Koot M, et al.: Reduced naive and increased activated CD4 and CD8 cells in healthy adult Ethiopians compared with their Dutch counterparts. Clin Exp Immunol 1999;115:443-450.
20. Rizzardini G, Piconi S, Ruzzante S, Fusi ML, Lukwiya M, Declich S, et al.: Immunological activation markers in the serum of African and European HIV-seropositive and seronegative individuals. AIDS 1996;10:1535-1542.
21. Barugahare B, Baker C, K'Aluoch O, Donovan R, Elrefaei M, Eggena M, et al.: Human immunodeficiency virus-specific responses in adult Ugandans: Patterns of cross-clade recognition. J Virol 2005;79:4132-4139.
22. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006;20:1391-1399.
23. Maecker H, Dunn h, Suni M, Khatamzas E, Pitcher L, Bunde T, et al.: Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods 2001;255:27-40.
24. Elrefaei M, El-Sheikh N, Kamal K, and Cao H: HCV-specific CD27- CD28- memory T cells are depleted in hepatitis C virus and Schistosoma mansoni co-infection. Immunology 2003;110: 513-518.
25. Vermes I, Haanen C, Steffens-Nakken H, and Reutelingsperger C: A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995;184:39-51.
26. Lecoeur H, Ledru E, Prevost MC, and Gougeon ML: Strategies for phenotyping apoptotic peripheral human lymphocytes comparing ISNT, annexin-V and 7-AAD cytofluorometric staining methods. J Immunol Methods 1997;209:111-123.
27. Hazenberg MD, Hamann D, Schuitemaker H, and Miedema F: T cell depletion in HIV-1 infection: How CD4+ T cells go out of stock. Nat Immunol 2000;1:285-289.
28. Badley AD, Dockrell DH, Algeciras A, Ziesmer S, Landay A, Lederman MM, et al.: In vivo analysis of Fas/FasL interactions in HIV-infected patients. J Clin Invest 1998;102:79-87.
29. Carbonari M, Pesce AM, Cibati M, Modica A, Dell'Anna L, D'Offizi G, et al.: Death of bystander cells by a novel pathway involving early mitochondrial damage in human immunodeficiency virus-related lymphadenopathy. Blood 1997;90:209-216.
30. - and SIV-infected lymph nodes. Nat Med 1995;1:129-134.
31. Katsikis PD, Wunderlich ES, Smith CA, and Herzenberg LA: Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. J Exp Med 1995;181:2029-2036.
32. Meyaard L, Otto SA, Jonker RR, Mijnster MJ, Keet RP, and Miedema F: Programmed death of T cells in HIV-1 infection. Science 1992;257:217-219.
33. Gougeon ML: Apoptosis as an HIV strategy to escape immune attack. Nat Rev Immunol 2003;3:392-404.
34. McCune JM: The dynamics of CD4+ T-cell depletion in HIV disease. Nature 2001;410:974-979.
35. Rodrigues MM, Cordey AS, Arreaza G, Corradin G, Romero P, Maryanski JL, et al.: CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. Int Immunol 1991;3:579-585.
36. Niehues T, McCloskey TW, Ndagijimana J, Horneff G, Wahn V, and Pahwa S: Apoptosis in T-lymphocyte subsets in human immunodeficiency virus-infected children measured immediately ex vivo and following in vitro activation. Clin Diagn Lab Immunol 2001;8:74-78.
37. Di Mascio M, Sereti I, Matthews LT, Natarajan V, Adelsberger J, Lempicki R, et al.: Naive T-cell dynamics in human immunodeficiency virus type 1 infection: Effects of highly active antiretroviral therapy provide insights into the mechanisms of naive T-cell depletion. J Virol 2006;80:2665-2674.
38. Valdez H, Connick E, Smith KY, Lederman MM, Bosch RJ, Kim RS, et al.: Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002;16:1859-1866.
39. Holm GH and Gabuzda D: Distinct mechanisms of CD4+ and CD8+ T-cell activation and bystander apoptosis induced by human immunodeficiency virus type 1 virions. J Virol 2005;79: 6299-6311.
40. Papagno L, Spina CA, Marchant A, Salio M, Rufer N, Little S, et al.: Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol 2004;2:E20.
41. Trimble LA and Lieberman J: Circulating CD8 T lymphocytes in human immunodeficiency virus-infected individuals have impaired function and downmodulate CD3 zeta, the signaling chain of the T-cell receptor complex. Blood 1998;91:585-594.
42. Trimble LA, Shankar P, Patterson M, Daily JP, and Lieberman J: Human immunodeficiency virus-specific circulating CD8 T lymphocytes have down-modulated CD3zeta and CD28, key signaling molecules for T-cell activation. J Virol 2000;74:7320-7330.
43. MacPherson PA, Fex C, Sanchez-Dardon J, Hawley-Foss N, and Angel JB: Interleukin-7 receptor expression on CD8(+) T cells is reduced in HIV infection and partially restored with effective antiretroviral therapy. J Acquir Immune Defic Syndr 2001;28:454-457.
44. Rethi B, Fluur C, Atlas A, Krzyzowska M, Mowafi F, Grutzmeier S, et al.: Loss of IL-7Ralpha is associated with CD4 T-cell depletion, high interleukin-7 levels and CD28 down-regulation in HIV infected patients. AIDS 2005;19:2077-2086.
45. Paiardini M, Cervasi B, Albrecht H, Muthukumar A, Dunham R, Gordon S, et al.: Loss of CD127 expression defines an expansion of effector CD8+ T cells in HIV-infected individuals. J Immunol 2005;174:2900-2909.
46. Napolitano LA, Grant RM, Deeks SG, Schmidt D, De Rosa SC, Herzenberg LA, et al.: Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: Implications for T-cell homeostasis. Nat Med 2001;7:73-79.
47. Beq S, Rannou MT, Fontanet A, Delfraissy JF, Theze J, and Colle JH: HIV infection: Pre-highly active antiretroviral therapy IL-7 plasma levels correlate with long-term CD4 cell count increase after treatment. AIDS 2004;18:563-565.
48. Zimmerli SC, Harari A, Cellerai C, Vallelian F, Bart PA, and Pantaleo G: HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci USA 2005;102:7239-7244.
49. Yu J, Chen H, Horton H, Bansal A, McElrath JM, Reichman R, et al.: Interleukin-2 reconstitutes defective human immunodeficiency virus (HIV), and cytomegalovirus (CMV) specific CD8+ T cell proliferation in HIV infection. J Med Virol 2006;78:1147-1157.
50. Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW, et al.: HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002;3:1061-1068.
51. Hunt PW, Deeks SG, Rodriguez B, Valdez H, Shade SB, Abrams DI, et al.: Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003;17:1907-1915.
52. Gulick RM, Meibohm A, Havlir D, Eron JJ, Mosley A, Chodakewitz JA, et al.: Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS 2003;17:2345-2349.
53. Viard JP, Burgard M, Hubert JB, Aaron L, Rabian C, Pertuiset N, et al.: Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS 2004;18:45-49.
54. Koblavi-Deme S, Maran M, Kabran N, Borget MY, Kalou M, Kestens L, et al.: Changes in levels of immune activation and reconstitution markers among HIV-1-infected Africans receiving antiretroviral therapy. AIDS 2003;17(Suppl. 3):S17-22.
55. Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, St Clair M, et al.: Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998;178:70-79.
56. Landay AL, Bettendorf D, Chan E, Spritzler J, Schmitz JL, Bucy RP, et al.: Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease. AIDS Res Hum Retroviruses 2002;18:95-102.
57. Bouscarat F, Levacher M, Dazza MC, Chau F, Desforges B, Muffat-Joly M, et al.: Prospective study of CD8+ lymphocyte activation in relation to viral load in HIV-infected patients with > or = 400 CD4+ lymphocytes per microliter. AIDS Res Hum Retroviruses 1999;15:1419-1425.
58. Vigano A, Saresella M, Rusconi S, Ferrante P, and Clerici M: Expression of CD38 on CD8 T cells predicts maintenance of high viraemia in HAART-treated HIV-1-infected children. Highly active antiretroviral therapy. Lancet 1998;352:1905-1906.
59. Connick E, Lederman MM, Kotzin BL, Spritzler J, Kuritzkes DR, St Clair M, et al.: Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis 2000;181:358-363.
60. Brenchley JM, Karandikar NJ, Betts MR, Ambrozak DR, Hill BJ, Crotty LE, et al.: Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 2003;101:2711-2720.
61. van Baarle D, Tsegaye A, Miedema F, and Akbar A: Significance of senescence for virus-specific memory T cell responses: Rapid ageing during chronic stimulation of the immune system. Immunol Lett 2005;97:19-29.
62. Scaling Up Anti-Retroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach, 2006 Revision. WHO, Geneva, 2006.